Tatva Chintan to use IPO proceeds for growth, not to repay debt: Chintan Shah“We would continue to spend 2% to 3% of revenue on R&D and that would translate into a strong top line growth.”
Vaccines and supply chains: A perfect storm?India is the world’s largest vaccine manufacturer, but the shortage it is facing currently says as much about poor governance as it does ab...
- EU slaps fines on 5 chemical giants
European Union regulators slapped five companies, including DuPont and Dow Chemical, with $358 million in fines on Wednesday for fixing the...